NCT05840042 Epidemiology and Risk Factors of Uterine Fibroids in China
| NCT ID | NCT05840042 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wenwen Wang |
| Condition | Uterine Fibroid |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2023-06-19 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2023-06-19 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Uterine fibroids are the most common form of benign uterine tumors in the uterine muscle layer, which had a certain rate of malignancy, but it is rare. The prevalence of uterine fibroids estimates range from 4.5% to 68.6% depending on study population and diagnostic methodology. The prevalence of fibroids has been historically underestimated by epidemiologic studies which focused mainly on symptomatic women, leaving behind a large population of asymptomatic women and women who underreport their symptoms. What investigators don't know was which women who have fibroids will develop clinical symptoms and which women who have an operation of myomectomy will relapse. The purpose of this study is to investigate the prevalence, incidence and risk factors for the development of uterine fibroids in Chinese women.
Eligibility Criteria
Inclusion Criteria: * Current place of residence≥ 6 months; * No serious mental illness or mental abnormality; * Those who agree to participate in this survey and cooperate in completing the questionnaire. Exclusion Criteria: \-
Contact & Investigator
SHIXUAN WANG, DOCTOR
PRINCIPAL INVESTIGATOR
Huazhong University of Science and Technology
Frequently Asked Questions
Who can join the NCT05840042 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Uterine Fibroid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05840042 currently recruiting?
Yes, NCT05840042 is actively recruiting participants. Contact the research team at petrawang@163.com for enrollment information.
Where is the NCT05840042 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT05840042 clinical trial?
NCT05840042 is sponsored by Wenwen Wang. The principal investigator is SHIXUAN WANG, DOCTOR at Huazhong University of Science and Technology. The trial plans to enroll 20,000 participants.